Sanofi: approval in COPD in the U.S.

(CercleFinance.com) - Sanofi announces that the US FDA has approved its Dupixent for the adjunctive maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype.


This approval is based on two landmark Phase III studies showing that Dupixent significantly reduced disease exacerbations, in addition to improving lung function and health-related quality of life, compared with placebo.

Dupixent is the number one biologic in terms of first prescriptions (NBRX), in all FDA-approved indications, and the most prescribed biologic by pulmonologists in the U.S.," says Sanofi.

Copyright (c) 2024 CercleFinance.com. All rights reserved.